Cancer clinical trials bounce back after significant COVID-19 disruption: Data from two large US cancer centers
Data from two large cancer centres in the United States have shown that the COVID-19 pandemic caused substantial disruption to clinical trials for cancer treatment and care. After a 46% decrease in new patient accruals, and a 24% decrease in newly activated trials between March and May 2020, a bounceback was seen in 2021. The findings suggest ways of improving the running of clinical trials and improving patients access to them worldwide.
Materials provided by European Society for Medical Oncology. Note: Content may be edited for style and length.
Source link aaaaa
